(Q36307876)

13 August 2017

1 reference

title

Recent advances in Parkinson's disease therapy: use of monoamine oxidase inhibitors (English)

1 reference

13 August 2017

1 reference

Claire Henchcliffe

1

1 reference

13 August 2017

H Christian Schumacher

series ordinal

2

1 reference

13 August 2017

F Tuna Burgut

series ordinal

3

1 reference

13 August 2017

publication date

1 November 2005

1 reference

Expert Review of Neurotherapeutics: a key contribution to decision making in the treatment of neurologic and neuropsychiatric disorders

13 August 2017

published in

1 reference

13 August 2017

volume

5

1 reference

13 August 2017

issue

6

1 reference

13 August 2017

page(s)

811-821

1 reference

Some observations upon a new inhibitor of monoamine oxidase in brain tissue.

13 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.811

The deamination of dopamine by human brain monoamine oxidase. Specificity for the two enzyme forms in seven brain regions

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.811

Multiple Forms of Human Brain Mitochondrial Monoamine Oxidase

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.811

Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.811

Evidence for dopamine deamination by both type A and type B monoamine oxidase in rat brain in vivo and for the degree of inhibition of enzyme necessary for increased functional activity of dopamine and 5-hydroxytryptamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.811

The Therapeutic Potential of Moclobemide, a Reversible Selective Monoamine Oxidase A Inhibitor in Parkinson's Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.811

A review of the mechanisms and role of monoamine oxidase inhibitors in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.811

Neuroprotection by monoamine oxidase B inhibitors: a therapeutic strategy for Parkinson's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.811

Molecular basis of neuroprotective activities of rasagiline and the anti-Alzheimer drug TV3326 [(N-propargyl-(3R)aminoindan-5-YL)-ethyl methyl carbamate].

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.811

Mechanism underlying anti-apoptotic activity of a (-)deprenyl-related propargylamine, rasagiline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.811

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.811

Rasagiline [N-propargyl-1R(+)-aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.811

Deprenyl in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.811

Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.811

Clinical pharmacokinetics and pharmacodynamics of selegiline. An update

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.811

A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.811

A new low-dose formulation of selegiline: clinical efficacy, patient preference and selectivity for MAO-B inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.811

Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: a 3-month, randomized, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.811

Neuroprotective effect of rasagiline, a selective monoamine oxidase-B inhibitor, against closed head injury in the mouse

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.811

Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.811

Tolerability, safety, pharmacodynamics, and pharmacokinetics of rasagiline: a potent, selective, and irreversible monoamine oxidase type B inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.811

Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.811

Rat striatal monoamine oxidase-B inhibition by l-deprenyl and rasagiline: its relationship to 2-phenylethylamine-induced stereotypy and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.811

A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.811

A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.811

Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.811

An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.811

N-Propargyl-1 (R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-kappaB transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.811

A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.811

Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.811

Autonomic effects of selegiline: possible cardiovascular toxicity in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.811

Selegiline-induced postural hypotension in Parkinson's disease: a longitudinal study on the effects of drug withdrawal

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.811

Cardiovascular activity of rasagiline, a selective and potent inhibitor of mitochondrial monoamine oxidase B: comparison with selegiline.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.811

Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. Parkinson's Disease Research Group of the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.811

Effect of selegiline on mortality in patients with Parkinson's disease: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.811

Malignant melanoma and levodopa in Parkinson's disease: causality or coincidence?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.811

21 January 2018

The serotonin syndrome

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.811

The neuropsychiatry of Parkinson's disease and related disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737175.5.6.811

21 January 2018

Identifiers

DOI

10.1586/14737175.5.6.811

1 reference

13 August 2017

1 reference